[go: up one dir, main page]

WO2013137912A3 - Méthodes de distribution de médicaments inhibant le complément aux patients recevant un inhibiteur de complément - Google Patents

Méthodes de distribution de médicaments inhibant le complément aux patients recevant un inhibiteur de complément Download PDF

Info

Publication number
WO2013137912A3
WO2013137912A3 PCT/US2012/029499 US2012029499W WO2013137912A3 WO 2013137912 A3 WO2013137912 A3 WO 2013137912A3 US 2012029499 W US2012029499 W US 2012029499W WO 2013137912 A3 WO2013137912 A3 WO 2013137912A3
Authority
WO
WIPO (PCT)
Prior art keywords
complement
methods
inhibiting drugs
patients
distributing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/029499
Other languages
English (en)
Other versions
WO2013137912A2 (fr
Inventor
Leonard Bell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Priority to EP12870989.6A priority Critical patent/EP2825989A4/fr
Priority to PCT/US2012/029499 priority patent/WO2013137912A2/fr
Priority to CN201280071445.8A priority patent/CN104205155A/zh
Priority to EA201400950A priority patent/EA201400950A1/ru
Priority to HK15105150.8A priority patent/HK1204693A1/xx
Publication of WO2013137912A2 publication Critical patent/WO2013137912A2/fr
Publication of WO2013137912A3 publication Critical patent/WO2013137912A3/fr
Priority to IL234680A priority patent/IL234680A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00—Control; Monitoring or safety arrangements
    • F04C2270/04—Force
    • F04C2270/041—Controlled or regulated

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention se rapporte aux méthodes pour autoriser la distribution de médicaments inhibant le complément à des patients qui ont des troubles associés à un complément de manière à garantir que les patients sont conscients des dangers possibles d'interruption du traitement avec les médicaments. Une base de données est préparée comprenant les informations sur les patients y compris les événements cliniques défavorables connus après l'interruption du traitement médicamenteux. Les informations de la base de données sont recueillies et peuvent être signalées. Les patients reçoivent un avertissement relatif aux événements défavorables qui peuvent survenir si un traitement avec les médicaments inhibant le complément est interrompu.
PCT/US2012/029499 2012-03-16 2012-03-16 Méthodes de distribution de médicaments inhibant le complément aux patients recevant un inhibiteur de complément Ceased WO2013137912A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP12870989.6A EP2825989A4 (fr) 2012-03-16 2012-03-16 Méthodes de distribution de médicaments inhibant le complément aux patients recevant un inhibiteur de complément
PCT/US2012/029499 WO2013137912A2 (fr) 2012-03-16 2012-03-16 Méthodes de distribution de médicaments inhibant le complément aux patients recevant un inhibiteur de complément
CN201280071445.8A CN104205155A (zh) 2012-03-16 2012-03-16 给接受补体抑制剂的患者分配补体抑制药物的方法
EA201400950A EA201400950A1 (ru) 2012-03-16 2012-03-16 Способы распространения комплемент-ингибирующих лекарственных средств среди пациентов, получающих ингибитор комплемента
HK15105150.8A HK1204693A1 (en) 2012-03-16 2012-03-16 Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor
IL234680A IL234680A0 (en) 2012-03-16 2014-09-16 Methods for distributing complement inhibitor drugs to patients receiving a complement inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/029499 WO2013137912A2 (fr) 2012-03-16 2012-03-16 Méthodes de distribution de médicaments inhibant le complément aux patients recevant un inhibiteur de complément

Publications (2)

Publication Number Publication Date
WO2013137912A2 WO2013137912A2 (fr) 2013-09-19
WO2013137912A3 true WO2013137912A3 (fr) 2014-05-01

Family

ID=49161929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/029499 Ceased WO2013137912A2 (fr) 2012-03-16 2012-03-16 Méthodes de distribution de médicaments inhibant le complément aux patients recevant un inhibiteur de complément

Country Status (6)

Country Link
EP (1) EP2825989A4 (fr)
CN (1) CN104205155A (fr)
EA (1) EA201400950A1 (fr)
HK (1) HK1204693A1 (fr)
IL (1) IL234680A0 (fr)
WO (1) WO2013137912A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3068424B1 (fr) * 2013-11-13 2020-09-09 Shire ViroPharma LLC Compositions et méthodes utiles pour le traitement de troubles du spectre de la neuromyélite optique
CN105260974A (zh) * 2015-09-10 2016-01-20 济南市儿童医院 一种生成具有告签功能的电子病历方法及系统
CN115177291B (zh) * 2022-08-01 2023-11-10 首都医科大学附属北京朝阳医院 用于识别重症监护病房获得性肌无力的方法和装置

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054403A1 (fr) * 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles associés au complément
WO2011091078A2 (fr) * 2010-01-19 2011-07-28 Xencor, Inc. Variants d'anticorps possédant une activité complémentaire accrue
US20110184747A1 (en) * 2006-08-09 2011-07-28 Carmen Bozic Method for distribution of a drug

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US20040117126A1 (en) * 2002-11-25 2004-06-17 Fetterman Jeffrey E. Method of assessing and managing risks associated with a pharmaceutical product
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20060062734A1 (en) * 2004-09-20 2006-03-23 Melker Richard J Methods and systems for preventing diversion of prescription drugs
DK2359834T5 (en) * 2006-03-15 2017-02-06 Alexion Pharma Inc Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor
US8478605B2 (en) * 2006-07-17 2013-07-02 Walgreen Co. Appropriateness of a medication therapy regimen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110184747A1 (en) * 2006-08-09 2011-07-28 Carmen Bozic Method for distribution of a drug
WO2010054403A1 (fr) * 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles associés au complément
WO2011091078A2 (fr) * 2010-01-19 2011-07-28 Xencor, Inc. Variants d'anticorps possédant une activité complémentaire accrue

Also Published As

Publication number Publication date
HK1204693A1 (en) 2015-11-27
WO2013137912A2 (fr) 2013-09-19
EA201400950A1 (ru) 2014-12-30
IL234680A0 (en) 2014-11-30
CN104205155A (zh) 2014-12-10
EP2825989A4 (fr) 2016-01-06
EP2825989A2 (fr) 2015-01-21

Similar Documents

Publication Publication Date Title
HK1211525A1 (en) Laquinimod and pridopidine for treating neurodegenerative disorders
MY166890A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX355065B (es) Método y dispositivo para conmutación de cámaras.
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
HK1211483A1 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
HK1198619A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2013138702A3 (fr) Méthodes de prévision des événements indésirables gastro-intestinaux immunitaires chez les patients traités par modulation de la voie de co‑stimulation
Giordano et al. Injectable and topical neurotoxins in dermatology: indications, adverse events, and controversies
GB2513675A (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
WO2014058979A8 (fr) Laquinimod pour réduire un dommage thalamique dans la sclérose en plaques
IN2015DN01975A (fr)
NZ606977A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
BR112014029260A2 (pt) medicamento para um ser humano ou um animal não humano, medicamento para anestesia geral, medicamento para a prevenção e/ou alívio de um déficit neurológico induzido por anestésico, método para parar o mesmo, uso de um anestésico geral, uso de uma anestésico geral e hidrogênio para a produção de um medicamento e método para prevenir e/ou aliviar um déficit neurológico induzido por anestésico
WO2013137912A3 (fr) Méthodes de distribution de médicaments inhibant le complément aux patients recevant un inhibiteur de complément
MX2013006564A (es) Uso de dronedarona para la preparacion de un farmaco para uso en la gestion del riesgo de daño hpatico.
JP2013520447A5 (fr)
HK1225972A1 (zh) 利用拉喹莫德来延缓亨廷顿氏病的进展
WO2014111790A3 (fr) Système d'administration de médicament pharmaceutique transdermique stable comprenant de la rivastigmine
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
WO2012145234A3 (fr) Dérivés cyclopropylés et leurs procédés d'utilisation
Guloksuz et al. A case of oxybutynin dependency.
Tuten et al. The role of significant others and family members in substance abuse treatment.
MX357376B (es) Composicion farmaceutica para uso en inflamacion y dolor.
McCammack Aspirin/clopidogrel/warfarin
Pendar Farahani THERAPEUTIC GAP, RACIAL GAP AND GENDER GAP FOR LDL-C GOAL ATTAINMENT IN INSURED PATIENTS WITH DIABETES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12870989

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 201400950

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2012870989

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12870989

Country of ref document: EP

Kind code of ref document: A2